These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 10351162)
1. Challenges in QA of leucodepleted blood component and current standard(s). Challenges in quality assurance of leukoreduced components. Dumont LJ Transfus Sci; 1998 Dec; 19(4):377-80. PubMed ID: 10351162 [No Abstract] [Full Text] [Related]
2. Logistical problems of supplying leucodepleted blood components within the national blood service. Tandy N Transfus Sci; 1998 Dec; 19(4):373-4. PubMed ID: 10351160 [No Abstract] [Full Text] [Related]
3. Leukodepleted blood components: definition of a standard. Andreu G; Masse M; Royer SD; Tardivel R Transfus Sci; 1998 Dec; 19(4):381-3. PubMed ID: 10351163 [No Abstract] [Full Text] [Related]
4. Operational and research approaches to universal leucodepletion in Scotland. Prowse C Transfus Sci; 1998 Dec; 19(4):367-9. PubMed ID: 10351158 [No Abstract] [Full Text] [Related]
5. International views on universal leucodepletion: the perspective in NBS, England. Wallington T Transfus Sci; 1998 Dec; 19(4):347-8. PubMed ID: 10351150 [No Abstract] [Full Text] [Related]
6. NBS approaches to the approval of suppliers of leucodepletion systems. Smith KJ Transfus Sci; 1998 Dec; 19(4):371-2. PubMed ID: 10351159 [No Abstract] [Full Text] [Related]
8. International views on universal leucodepletion: the perspective in Portugal. de Sousa G Transfus Sci; 1998 Dec; 19(4):351-2. PubMed ID: 10351152 [No Abstract] [Full Text] [Related]
9. International views on universal leucodepletion: the perspective in NBS, Ireland. Murphy W Transfus Sci; 1998 Dec; 19(4):349-50. PubMed ID: 10351151 [No Abstract] [Full Text] [Related]
10. International views on universal leucodepletion: the perspective in Germany. Seitz MD Transfus Sci; 1998 Dec; 19(4):359-60. PubMed ID: 10351155 [No Abstract] [Full Text] [Related]
11. Perspective on Nordic views on selective/universal leukodepletion. Flesland O Transfus Sci; 1998 Dec; 19(4):355-7. PubMed ID: 10351154 [No Abstract] [Full Text] [Related]
12. French evaluation of conditions for the systematic implementation of leucocyte removal in labile blood products (LBP). Chamfly V Transfus Sci; 1998 Dec; 19(4):333-42. PubMed ID: 10351148 [No Abstract] [Full Text] [Related]
13. Developing effective working partnership with manufacturers. Pujol-Reyz A Transfus Sci; 1998 Dec; 19(4):375-6. PubMed ID: 10351161 [No Abstract] [Full Text] [Related]
14. International views on universal leucodepletion: the perspective in The Netherlands. de Wit HC Transfus Sci; 1998 Dec; 19(4):353-4. PubMed ID: 10351153 [No Abstract] [Full Text] [Related]
16. Validation approaches selective/universal leucodepletion: the need for standardised validation strategies. Seghatchian MJ; Krailadsiri P Transfus Sci; 1998 Dec; 19(4):363-5. PubMed ID: 10351157 [No Abstract] [Full Text] [Related]
17. NBA/NBS perspective on nvCJD. Wallington T Transfus Sci; 1998 Dec; 19(4):329-30. PubMed ID: 10351146 [No Abstract] [Full Text] [Related]
18. Automation in quality assurance of blood components and the complementary role of audit. Seghatchian MJ Transfus Sci; 1995 Sep; 16(3):223-8. PubMed ID: 10159876 [No Abstract] [Full Text] [Related]
19. The risk of transmission of nvCJD by blood transfusion and the potential benefits of leucodepletion. Turner M Transfus Sci; 1998 Dec; 19(4):331-2. PubMed ID: 10351147 [No Abstract] [Full Text] [Related]